Unknown

Dataset Information

Acetylcysteine increases sensitivity of ceftazidime-avibactam-resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo.


ABSTRACT:

Background

Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.

Results

This study found that NAC combined with CZA effectively inhibits the growth of CZA-resistant clinical Enterobacterales strains. The CZA/NAC combination inhibits biofilm formation in vitro and decreases bacterial burden in a mouse thigh infection model. The combination is biocompatible and primarily increases cell membrane permeability to cause bacterial death.

Conclusions

These findings prove that the CZA/NAC combination has potential as a treatment for CZA-resis

SUBMITTER: Huang Z 

PROVIDER: S-EPMC10623744 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature